In 2024, the Global Re-Imbursed Pharmaceutical Market by country shows significant variance. New Zealand leads with 36.2% of generics in value, reflecting a favorable trend of 2.05% year-on-year increase from 2023. Germany, despite holding second place at 27.6%, experienced a decline of 3.16%. Portugal stands at 25.1%, with a slight decrease of 0.24%. Spain demonstrates positive momentum at 23.6%, up by 1.05%. Canada, at 22.4%, shows a notable decline of 4.09%. Switzerland remains stable at 20.1% with zero variation, while Austria and Belgium show declining trends at 12.7% and 11.5%, down by 1.5% and 2.87% respectively.
Future trends to watch for in the Global Re-Imbursed Pharmaceutical Market by country include:
- Potential rise in generic adoption in countries showing decline.
- Impact of healthcare policy changes on market distribution.
- Advances in biotech and biosimilars influencing generics' market share.
- Cost-containment measures by governments affecting the overall market.
- Evolving consumer preferences towards generic pharmaceuticals.
Top countries in Re-Imbursed Pharmaceutical Market by Country
| # | 8 Countries | Percent of Generics in Value | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 New Zealand | 36.2 | 2023 | -6.22% | +2.05% | View data |
| 2 | 2 Germany | 27.6 | 2023 | -2.47% | -3.16% | View data |
| 3 | 3 Portugal | 25.1 | 2023 | +1.21% | -0.24% | View data |
| 4 | 4 Spain | 23.6 | 2023 | +2.61% | +1.05% | View data |
| 5 | 5 Canada | 22.4 | 2023 | -4.68% | -4.09% | View data |
| 6 | 6 Switzerland | 20.1 | 2023 | +1.01% | 0% | View data |
| 7 | 7 Austria | 12.7 | 2023 | -0.78% | -1.5% | View data |
| 8 | 8 Belgium | 11.5 | 2023 | -0.86% | -2.87% | View data |
